Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UU Scientists Developing Breakthrough Diabetes Drugs

07.10.2005


University of Ulster scientists are developing innovative drugs that could represent important new therapeutic tools to help ease the burden of diabetes worldwide. The news comes as a UN World Health Organisation report identifies diabetes as one of the major health issues facing the world in the 21st century.



The research team at UU have discovered that modified-forms of GIP, a naturally occurring molecule produced by the body, can combat key symptoms of diabetes. This stimulated the formation of a new company to develop production of new anti-diabetic agents.

Current statistics report some 150 million diagnosed cases of diabetes worldwide, and that figure is set to double within 20 years, according Dr Neville McClenaghan, a prime mover in the new company Diabetica Limited.


“The holy grail of diabetes treatment is safe and effective management of blood glucose. We believe that novel molecules arising from our platform GIP technology should provide effective new tools to help individuals better control the condition known as Type 2 diabetes,” he said.

“That’s really what physicians are looking for at the minute - new drugs that offer improvements or enhancement over current drugs.”

Diabetes is a complex metabolic disorder clinically defined by high blood glucose levels resulting from a relative or absolute absence of insulin-production coupled with defective insulin action in body tissues. The latter is a defining characteristic of the ‘metabolic syndrome’ and is an important link between Type 2 diabetes and other conditions including obesity, heart disease and stroke.

In diabetes there is a breakdown in the person’s ability to regulate blood-glucose levels, and thus pharmacological treatments are required to bring the blood glucose levels back down to safe levels.

The main pharmacological approaches to the treatment of diabetes are focussed on replacing insulin by injection or the use of drugs, which either increase circulating insulin or enhance its action on insulin-sensitive tissues.

“Diabetes and the related conditions, metabolic syndrome and obesity, are reaching epidemic proportions and thus are major healthcare challenges. This clearly prompts the development of new and innovative approaches for effective management and treatment of this complex disease” said Dr McClenaghan.

Years of research by the team at UU have culminated in two distinct therapeutic products developed from the gut peptide, GIP, which is released into the blood following eating. Preclinical studies have revealed that both therapeutic products exhibit potent glucose-lowering actions mediated by either increasing circulating insulin or enhancing insulin action.

“We have discovered that strategic bio-engineering of the GIP molecule can generate stable long-acting forms with two principal modes of anti-diabetic action and have patent-protected the technology,” he said.

“Diabetica’s therapeutic GIP products have generated a lot of interest. GIP-based therapies are exciting new approaches which offer considerable advantages over existing and emerging diabetes/obesity therapies, which suffer from shortcomings such as poor efficacy, difficult dosing regimens and adverse side effects. This is a very exciting time for Diabetica as our two novel GIP drugs - Incretide and Metalog - could provide a major advance in the effective management of diabetes, metabolic syndrome and obesity.”

The co-founders of Diabetica Limited - Professor Peter Flatt, Professor Finbarr O’Harte and Dr Neville McClenaghan - established the Coleraine-based biotechnology company last year as a first step to achieving a sound commercial footing for product development.

In June, the University’s technology transfer arm, UUTech Limited and Seroba BioVentures Limited, a life sciences venture capital fund, announced that they would provide funding for Diabetica’s pre-clinical testing programmes.

Dr McClenaghan said: “We now wish to take our GIP drugs through formal clinical evaluation. Clinical trials are a vital step along the way to full approval and prescribed use of any drug. Diabetica’s GIP drugs, Incretide and Metalog, are two distinctly different products addressing the major unmet need for “smart therapeutics” whose actions are regulated by circulating levels of blood glucose. Thus, we anticipate that Incretide and Metalog will offer the individual immediate advantages associated with better control of blood glucose levels and reducing the likelihood of development of complications associated with long-term hyperglycaemia.”

The increasing global incidence of diabetes has led to major investments by the bio-pharmaceutical industry to develop and acquire therapeutic, drug delivery and diagnostic solutions for diabetes and obesity, creating significant opportunities for Diabetica’s novel therapeutics as the anti-diabetic and anti-obesity drugs of tomorrow.

Brian O’Connor, Chairman of UUTech said: “UUTech is pleased at the progress made so far and will work to ensure that Diabetica has the best possible chance of success during the development phase of this exciting science over the next several years."

“We are delighted with the validation this funding gives to our technology,” said Matt O’Driscoll, Chief Executive Officer of Diabetica. “This is the first stage in a fundraising and corporate partnering campaign over the next 12 months designed to push the development of our lead GIP molecules into the clinic.”

David Young | alfa
Further information:
http://www.ulster.ac.uk
http://www.ulster.ac.uk/news/releases/2005/1860.html

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>